Gilead Quad’s Side Effects Profile, Novel Agents To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.